OpenAI 收购 AI 生物科技初创公司 Orchestra Bio
OpenAI acquires startup Orchestra Bio to beef up its biotech business
OpenAI 于周二宣布收购成立四年的 AI 生物科技软件初创公司 Orchestra Bio，交易条款未披露，该公司截至 2025 年已融资约 2000 万美元，投资方包括 Andreessen Horowitz、Atria 和 8VC。
同一件事另外 1 家也报道了
- TechCrunch · AI··首发·当前阅读
OpenAI 收购 AI 生物科技初创公司 Orchestra Bio
- The Decoder··+11 小时 58 分
OpenAI 收购 Orchestra Bio，拟打造加速药物研发的 AI 智能体
新增信息：OpenAI 提到在美国开发一款药物平均需要 10 到 15 年。
按发布时间排列 · 事件后续出现时自动追加 · 由模型根据各家标题与摘要比对
In Brief
Posted:
1:35 PM PDT · October 20, 2026
OpenAI on Tuesday acquired a four-year-old AI biotech software startup called Orchestra Bio, the company announced on its website. Terms of the deal were not disclosed, but the startup had reportedly raised around $20 million as of 2025 from backers like Andreessen Horowitz, Atria, and 8VC.
Orchestra creates AI agents that help biotech companies manage the minutiae of drug-discovery operations, from tracking finances to resolving scheduling issues with clinical trials.
OpenAI says it’s adding Orchestra’s team and technology to work on Rosalind, its AI model for life sciences research, and to its related Rosalind Workbench tool, a harness that aims to help researchers plan experiments and analyze results. OpenAI has already won some big names as customers for Rosalind, including, it says, Moderna and Novo Nordisk.
The acquisition is a classic example of how the biggest AI labs (namely OpenAI and Anthropic) are building ever more software for the biggest industries, like pharma. In the startup world, there is an ongoing fear that at any moment, the labs will launch new features and become competitors. In this case, Orchestra is getting absorbed, rather than stomped out.
来源: TechCrunch · AI · techcrunch.com